MSU MFA Program in Science & Natural History Filmmaking

America Has a Hidden Health Crisis Leaching from Our Grout

Retrieved on: 
목요일, 10월 5, 2023
Foot, Floor, Poisoning, Organic compound, United States Forest Service, Plant, Family, Lowe's, Lead, Pesticide, Brain, Liver, Animal, Volatile organic compound, Safety, Transport, Environmental toxicology, United States Environmental Protection Agency, Mercury, Pet, Cancer, EPA, Environment, MSU MFA Program in Science & Natural History Filmmaking, Infertility, Silver, Grout, Neoplasm, Birth, Walmart, Name, Metal, Water, Tile, Road, Bottled water, Amazon, Health, Rail profile

MARIETTA, Ga., Oct. 5, 2023 /PRNewswire-PRWeb/ -- What's Lurking in Your Grout?

Key Points: 
  • The problem is that tile is installed with grout and grout is made with many potentially harmful or hazardous materials.
  • Many of the chemicals added to grout are biocides or toxins that have been rated as high-level carcinogens.
  • Many grout manufacturers claim their products are "green" or environmentally friendly, yet they still include biocides in their grout to make marketing claims.
  • When choosing grout, it is essential to consider both the environment and the health of those living in your home.

Vedanta Biosciences to Participate in the JMP Securities Life Sciences Conference

Retrieved on: 
수요일, 6월 8, 2022
Health, Other Health, Other Science, General Health, Research, Science, Biotechnology, LBP, PRTC, Liver disease, Conference, Research, Lotte New York Palace Hotel, LSE, MSU MFA Program in Science & Natural History Filmmaking, Inflammatory Bowel Diseases, List of life sciences, Cell, Library, Doctor of Philosophy, Immune system, Food allergy, Bacteria, PureTech Health, Cancer, Pharmaceutical industry, Science, Nature

Vedanta Biosciences , a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced that Bernat Olle, Ph.D., Chief Executive Officer of Vedanta Biosciences, will participate in a fireside chat at the JMP Securities Life Sciences Conference being held June 15-16, 2022 at the Lotte New York Palace in New York, NY.

Key Points: 
  • Vedanta Biosciences , a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced that Bernat Olle, Ph.D., Chief Executive Officer of Vedanta Biosciences, will participate in a fireside chat at the JMP Securities Life Sciences Conference being held June 15-16, 2022 at the Lotte New York Palace in New York, NY.
  • Vedanta Biosciences is leading the development of a potential new category of oral therapies based on defined consortia of bacteria isolated from the human microbiome and grown from pure clonal cell banks.
  • Vedanta Biosciences controls a foundational portfolio of more than 45 patents and has built what it believes is one of the largest libraries of bacteria derived from the human microbiome.
  • Vedanta Biosciences was founded by PureTech Health (Nasdaq: PRTC, LSE: PRTC) and a global team of scientific co-founders who pioneered the modern understanding of the cross-talk between the microbiome and the immune system.

Vedanta Announces Positive Topline Phase 2 Data for VE303 in High-Risk C. difficile Infection and Exercise of $23.8 Million Option by BARDA

Retrieved on: 
화요일, 10월 5, 2021
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, Mortality, PCR, Medical microbiology, Clinical trial, Assistant, Inflammatory Bowel Diseases, Orphan, Diagnosis, Recurrence, Infection, Therapy, United States Department of Health and Human Services, Doctor of Philosophy, Biomedical Advanced Research and Development Authority, Patient, Death, Population, Feces, BARDA, HHS, Development, MSU MFA Program in Science & Natural History Filmmaking, University, Disease, Odds ratio, Bacteria, Immune system, List of life sciences, Contract manufacturing organization, PRTC, LSE, CDI, Risk, Food allergy, Cell, Office of the Assistant Secretary for Preparedness and Response, Research, LBP, PureTech Health, Safety, Data analysis, Clostridioides difficile infection, Department, Pharmaceutical industry, Medical device, Antibiotics, VE303, Vedanta Biosciences, VE303, VEDANTA BIOSCIENCES

We believe these results are an important step forward for the prevention of C. difficile infection and the microbiome field at large.

Key Points: 
  • We believe these results are an important step forward for the prevention of C. difficile infection and the microbiome field at large.
  • Recurrent CDI causes approximately half a million infections each year in the United States, including up to 165,000 recurring infections and up to 45,000 deaths.
  • Based on the Phase 2 data, BARDA has exercised its first contract option for additional funding of $23.8 million pursuant to its existing 2020 contract with Vedanta.
  • Total committed funding under the BARDA award to date is $31.2 million, inclusive of this first contract option.

Voucher Shares launches Green Icon to make Sustainable Online Shopping easier

Retrieved on: 
화요일, 8월 10, 2021
COO, CEO, Deloitte, Nature, World Land Trust, Entrepreneurship, WLT, Heart, Friends, Human, Sustainability, Free Enterprise Action Fund, MSU MFA Program in Science & Natural History Filmmaking, Marketing, Online shopping, Bookkeeping

"Voucher Shares, the UK's first green voucher codes website, was launched just before the pandemic.

Key Points: 
  • "Voucher Shares, the UK's first green voucher codes website, was launched just before the pandemic.
  • Combined with thousands of voucher codes , deals, and exclusive offers, we make sustainable shopping easier and more affordable for everyone.
  • This makes any online shopping through the Voucher Shares website more sustainable than shopping with brands directly."
  • Shopping sustainably with Voucher Shares cannot be easier:
    About Voucher Shares: Voucher Shares is part of Codes To Share limited and is based in the UK.